Schedule
Schedule
Schedule
Publicly funded vaccines may be provided only to eligible persons and must be free of charge.
SCHEDULE 1. Routine Schedule for Children Beginning Immunization in Early Infancy (Starting at 2 months of age)
Age at vaccination:
Completed months and years
DTaP-IPV1-Hib2
Pneu-C-133
Rot-14
Men-C-C5
MMR6
Var 7
MMRV8
Men-C-ACYW9
HB10
HPV-411
Tdap12
Inf 13
2 months old
4 months old
6 months old
12 months old
15 months old
18 months old
4-6 years old
Grade 7 students
Grade 8 females
**
*DTaP-IPV preferably given at 4 years of age; administer to children <6 years old, see Schedule 3. For Pneu-C-13 high risk schedule, see Table 3. MMRV preferably given at 4 years of age. Administered
through school-based program. See Schedule 4 for adult Td immunization. **Previously unimmunized children <9 years receive 2 doses of Inf 4 weeks apart.
Notes:
High risk: For high risk eligibility criteria, please see
page 3.
Catch-up: for catch-up schedules, please refer to
Schedules 2 and 3.
Interruption of a vaccine series does not require
restarting the series, regardless of the length of time
elapsed since the last dose.
Up to date immunization records or valid exemptions
are required for attendance at school (Immunization of
School Pupils Act) and licensed daycare centres (Day
Nurseries Act) in Ontario.
Vaccine Administration:
Never mix and administer different vaccines
together in the same syringe unless indicated in the
product monograph.
Route of administration:
Intramuscular (IM): DTaP-IPV-Hib, DTaP-IPV, Tdap,
Td, HA, HB, HPV-4, Men-C-C, Men-C-ACYW, Inf, and
Pneu-C-13.
Subcutaneous (SC): MMR, Var, MMRV, and IPV
(if given as a separate antigen).
IM or SC: Pneu-P-23
Oral (PO): Rot-1
Refer to the Canadian Immunization Guide (CIG), 7th edition (2006) (or as current) for additional information regarding
recommendations for immunocompromised individuals.
(Available online at: http://www.phac-aspc.gc.ca/publicat/cig-gci/pdf/cig-gci-2006_e.pdf; Guide errata and clarifications, March 2008. Available at: http://www.phac-aspc.gc.ca/publicat/cig-gci/errarta-eng.php)
For vaccines not publicly funded, please refer to NACI statements, and the individual product monographs for indications and usage.
Available at: http://www.phac-aspc.gc.ca/naci-ccni/recs-eng.php
For more information and to report adverse events following immunization (AEFIs) contact your local public health unit at:
The National AEFI reporting form and User Guide are available at:
http://www.phac-aspc.gc.ca/im/aefi-form-eng.php
For more detailed vaccine information, consult the manufacturers product monograph, Canadian Immunization Guide,
or the National Advisory Committee on Immunization website at:
http://www.phac-aspc.gc.ca/naci-ccni/index.html
References:
National Advisory Committee on Immunization. Statement on Seasonal Trivalent Inactivated Influenza Vaccine (TIV) for 2010-2011, CCDR, Volume 36,
ACS-6; August 2010.
National Advisory Committee on Immunization. Statement on Human Papillomavirus Vaccine, CCDR, Volume 33, ACS-2: February 15, 2007.
National eligible, due, and overdue guidelines for immunization registries: Draft recommendations from the Canadian Immunization Registry Network Data
Standards Task Group. CCDR 15 March 2004 Volume 30 Number 06. Available at: http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/04vol30/dr3006e.html
A physician, a member of the College of Nurses of Ontario or a member of the Ontario College of Pharmacists who,
while providing professional services to a person, recognizes the presence of a reportable event and forms the opinion that it may
be related to the administration of an immunizing agent shall, within seven days after recognizing the reportable event, report thereon
to the medical officer of health of the health unit where the professional services are provided.
Vaccine Antigen Abbreviations: DTaP = diphtheria, tetanus, acellular pertussis; IPV = inactivated poliovirus; Hib = haemophilus influenzae type b; Pneu-C-13 = pneumococcal
conjugate-13 valent; Rot-1 = rotavirus ORAL; MMR = measles, mumps, rubella; MMRV = measles, mumps, rubella, varicella; Men-C-C = meningococcal conjugate C;
Men-C-ACYW = meningococcal conjugate ACYW-135; Var = varicella zoster; HA = hepatitis A; HB = hepatitis B; Tdap = tetanus, diphtheria, acellular pertussis ;
Td = tetanus, diphtheria; Inf = seasonal influenza; HPV-4 = human papillomavirus quadrivalent; Pneu-P-23 = pneumococcal polysaccharide-23 valent
Publicly funded vaccines may be provided only to eligible persons and must be free of charge.
Publicly funded vaccines may be provided only to eligible persons and must be free of charge.
TABLE 3: Detailed HIGH RISK schedule for Pneumococcal Conjugate-13 vaccine depending on age at first dose
SCHEDULE 2. Catch-up Schedule for Children Starting Immunization at 1-6 years of age
Timing
DTaP-IPV -Hib
Pneu-C-13
( )
Men-C-C
MMR
Var
MMRV
Men-C-ACYW
HB
HPV-4
10
Tdap
11
12
( )
Primary series
2-6 months
15 months
7-11 months
15 months
12-23 months
None
24-59 months
1 dose
None
Inf
13
Children 2 years of age, at high risk of invasive pneumococcal disease, should also receive a dose of Pneu-P-23 at least 8 weeks after the Pneu-C-13.
( )
( )
TABLE 4: Detailed schedule for Varicella vaccine for HIGH RISK persons depending on age
( )*
Grade 7
12 months-12 years
Special considerations/restrictions are required for the immunocompromised (see Canadian Immunization Guide, 7th ed, 2006). Available at: http://www.phac-aspc.gc.ca/publicat/cig-gci/pdf/cig-gci2006_e.pdf Guide errata and clarifications, March 2008. Available at: http://www.phac-aspc.gc.ca/publicat/cig-gci/errarta-eng.php
Grade 8 females
Timing
**
( ) Depending on age of child, dose may not be needed. *If 4th dose of DTaP-IPV is given on or after the 4th birthday, the 4-6 year old booster dose is not needed. Administer Hib to children <5 years of age.
Administer Pneu-C-13 to children <5 years of age. Children between 4-11 years of age are eligible to receive MMRV. Administered through school-based program. **Previously unimmunized children <9
years receive 2 doses of Inf 4 weeks apart.
Tdap12
Td
IPV
MMR6
Var7
MMRV8
Men-C-ACYW9
HB10
HPV-411
Inf13
( )*
( )*
1. Pneumococcal Conjugate Vaccine: All children <5 years of age should be vaccinated
with Pneu-C-13 vaccine as per Schedules 1 and 2.
Grade 8 females
( ) Depending on age of child, dose may not be needed. *Administer Var to children born on or after January 1, 2000. Administered through school-based program. Students who missed a dose who were
previously in Grade 7 in or after 2009 remain eligible for Men-C-ACWY. Those born in 1996 or before should receive Men-C-C. Previously unimmunized children <9 years receive 2 doses of Inf 4 weeks apart.
Tdap12
Td
IPV
( )*
( )*
( )*
( )*
st
MMR6
Inf 13
Pneu-P-23
( )
2-6 months
15 to 18 months
7-11 months
15 to 18 months
12-14 months
1 dose
15 to 18 months
15-59 months
1 dose
None
1. All residents of nursing homes, homes for the aged and chronic care facilities
or wards.
2. All persons 65 years of age and older regardless of medical condition.
Meningococcal Vaccines
A. Meningococcal Conjugate C Vaccine (1-10 yrs)
1. All persons with functional or anatomic asplenia.
2. All persons with complement, properdin, factor D deficiency or primary antibody
deficiencies3.
3. Cochlear implant recipients (pre/post implant).
B. Meningococcal Conjugate ACYW-135 Vaccine (2-55 yrs)
1. All persons with functional or anatomic asplenia.
2. All persons with complement, properdin, factor D deficiency or primary antibody
deficiencies3.
3. Cochlear implant recipients (pre/post implant).
The Hib booster dose should be given at least 2 months after the previous dose.
TABLE 2: Detailed LOW RISK schedule for Pneumococcal Conjugate-13 vaccine depending on age at first dose
Primary series
2-6 months
12 months
7-11 months
12 to 15 months
12-23 months
None
24-59 months
1 dose
None
2. Pneumococcal Polysaccharide Vaccine: For children <5 years old, the Pneu-P-23
vaccine should be given at least 8 weeks after the Pneu-C-13 vaccine1. All persons 2
years of age with the medical conditions listed below should receive one dose of the
Pneu-P-23 vaccine:
Chronic respiratory disease (excluding asthma, except those treated with highdose corticosteroid therapy1,2)
Chronic cardiac disease
Chronic liver disease (including hepatitis B and C, and hepatic cirrhosis due to any
cause)
Chronic renal disease, including nephrotic syndrome
Diabetes mellitus
Chronic cerebrospinal fluid leak
Chronic neurologic condition that may impair clearance of oral secretions
Asplenia (functional or anatomic), splenic dysfunction, sickle-cell disease and
other sickle cell haemoglobinopathies
Primary immune deficiency
Congenital immunodeficiencies involving any part of the immune system, including
B-lymphocyte (humoral) immunity, T-lymphocyte (cell) mediated immunity,
complement system (properdin, or factor D deficiencies), or phagocytic functions
Other conditions associated with immunosuppression (e.g., malignant neoplasms,
including leukemia and lymphoma)
Immunosuppressive therapy including use of long-term systemic corticosteroid,
chemotherapy, radiation therapy, post-organ transplant therapy, certain antirheumatic drugs and other immunosuppressive therapy
HIV infection
Hematopoietic stem cell transplant (candidate or recipient)
Solid organ or islet cell transplant (candidate or recipient)
Cochlear implant recipients (pre/post implant)
Number of doses
Varicella Vaccine
1. Susceptible children and adolescents given chronic salicylic acid therapy (consider
stopping treatment for 6 weeks after vaccination, see product monograph).
2. All persons with cystic fibrosis.
3. Susceptible household contacts of immunocompromised persons.
4. Susceptible persons receiving low dose steroid therapy or inhaled/topical steroids.
5. Immunocompromised persons,2,3,5 see the CIG, 7th ed. (or as current) for varicella
vaccination recommendations regarding specified susceptible immunocompromised
individuals.
For the recommended number of doses for susceptible high risk persons, see CIG, 7th ed.
Hepatitis B Vaccine
1. Infants born to HBV-positive carrier mothers.
2. Household and sexual contacts of chronic carriers and acute cases.
3. Persons on renal dialysis and those with diseases requiring frequent receipt of blood
products (e.g., haemophilia) (second and third doses only).
4. Persons awaiting liver transplants (second and third doses only).
5. Injection drug users.
6. Men who have sex with men, individuals with multiple sex partners, history of a
sexually transmitted infection.
7. Those having needle stick injuries in a non-health care setting.
8. Children <7 years old whose families have immigrated from countries of high
prevalence for hepatitis B, and who may be exposed to hepatitis B carriers through
their extended families.
9. Persons with chronic liver disease including hepatitis C.
Hepatitis A Vaccine
1. Persons with chronic liver disease (including hepatitis B and C).
2. Persons engaging in intravenous drug use.
3. Men who have sex with men.
Note: for post exposure immunization with hepatitis A vaccine, consult with your local
public health unit on the appropriate requirements based on age and/or immunization
history.
N
ational Advisory Committee on Immunization. Update on the use of conjugate pneumococcal vaccines in childhood. Canada Communicable Disease Report Volume 36, November
2010. Available at: http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/10vol36/acs-12/index-eng.php
2
C
ompendium of Pharmaceuticals and Specialties, 2005: the Canadian drug reference for health professionals
3
N
ational Advisory Committee on Immunization. Update on the invasive meningococcal disease and meningococcal vaccine conjugate recommendations. Canada Communicable
Disease Report. Volume 36, April 2009. Available at: http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/09vol35/acs-dcc-3/index-eng.php
4
N
ational Advisory Committee on Immunization. Canadian Immunization Guide (CIG), 2006, 7th edition. Public Health Agency of Canada, 2006. Available at: http://www.phac-aspc.
gc.ca/publicat/cig-gci/pdf/cig-gci-2006_e.pdf Guide errata and clarifications, March 2008. Available at: http://www.phac-aspc.gc.ca/publicat/cig-gci/errarta-eng.php
5
N
ational Advisory Committee on Immunization. Updated recommendations for the use of Varicella and MMR Vaccines In HIV-infected Individuals. Communicable Disease Report.
Volume 36; ACS-7 September 2010.
* The Pneu-C-13 booster dose should be given at least 2 months after the final dose of the primary series.
contd
2